June 19, 2020
Bloomberg Law
As generic drug makers compete for first-filer status of generic versions of branded products, the pharmaceutical industry has seen an increase in litigation from brand-name drug makers to defend their patents from multiple companies for a single drug. In addition to increased pressure for transparency over drug prices, there are concerns over whether the current system is beneficial for drug makers and consumers. Bloomberg Law contacted Finnegan partner Scott Burwell for his thoughts.
Scott commented on the impact the trend of increased first-filers is having on litigation. He said, “It does increase the complexity and the cost of litigation because the innovators now have multiple fronts on which to fight.”
Read the full article here.
Award/Ranking
Managing IP Americas Awards 2024: Finnegan Shortlisted for Nine Awards, Including Firm of the Year
March 12, 2024
Commentary
February 29, 2024
Press Release
Finnegan Secures Another Patent Victory for BMW Group in the District of Delaware
February 27, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.